2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2110 Zanubrutinib plus venetoclax demonstrates durable efficacy across TP53 aberration and IGHV subgroups in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): 4-year follow-up of SEQUOIA arm D

Mazyar Shadman, MD, MPH, Talha Munir, MBBS, MRCP , PhD2, Shuo Ma, MD3, Masa Lasica4, Monica Tani5, Tadeusz Robak, MD6, Ian W. Flinn, MD, PhD7, Jennifer R. Brown, MD, PhD8, Paolo Ghia, MD, PhD9, Emmanuelle Ferrant, MD10, Constantine S. Tam, MD,MBBS11, Wojciech Janowski, MBChB FRACP FRCPA12, Wojciech Jurczak, MD, PhD13, Marcus Lefebure, PhD14, Linlin Xu15, Jiayi Shen16, Wassim Aldairy17, Jamie Hirata, PharmD18, Alessandra Tedeschi19
1 Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington, United States
2 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
3 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
4 St Vincent's Hospital Melbourne, Melbourne, Australia
5 Santa Maria delle Croci Hospital, Ravenna, Italy
6 Medical University of Lodz, Lodz, Poland
7 Tennessee Oncology/OneOncology, Nashville, Tennessee, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Comprehensive Cancer Center, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
10 CHU de Lyon-Sud, Lyon-Sud, France
11 Alfred Hospital and Monash University, Melbourne, Australia
12 Calvary Mater Newcastle Hospital, Waratah, Australia
13 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
14 BeOne Medicines, London, United Kingdom
15 BeOne Medicines, San Carlos, California, United States
16 BeOne Medicines, San Carlos, California, United States
17 BeOne Medicines, San Carlos, California, United States
18 BeOne Medicines, San Carlos, California, United States
19 ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Introduction: TP53 aberrations, including del(17p) and TP53 mutations (TP53mut), and unmutated immunoglobulin heavy-chain variable region (uIGHV) status are adverse prognostic factors in TN CLL/SLL, associated with inferior outcomes and earlier disease progression, even with targeted therapies. Arm D of the phase 3 SEQUOIA study (NCT03336333) evaluated zanubrutinib (zanu) + venetoclax (ven) in patients (pts) with TN CLL/SLL, enriched in those with del(17p) and/or TP53mut. Previously reported results demonstrated high rates of progression-free survival (PFS), deep undetectable minimal residual disease (uMRD) responses, and manageable safety at a median follow-up (mFU) of 31 months (mo) (Shadman et al. JCO 2025). Here, we present outcomes with ~4 years mFU, with a focus on TP53 aberrations and IGHV status.

Methods: Pts were aged ≥65 years or aged 18-64 years with comorbidities. Participants received zanu 160 mg BID for a 3-cycle lead-in, followed by ven dose ramp-up to 400 mg QD from Cycle 4 and combination treatment through Cycle 28. Thereafter, pts continued zanu monotherapy until progressive disease (PD), unacceptable toxicity, or protocol-defined uMRD-guided treatment discontinuation. Endpoints included PFS, overall survival, uMRD (defined as <1×10-4 by flow cytometry in peripheral blood [PB] and bone marrow on two consecutive assessments performed ≥12 weeks apart in pts achieving complete response or complete response with incomplete hematopoietic recovery), and safety. Outcomes were analyzed according to TP53 aberration status [del(17p) and/or TP53mut vs without] and IGHV status (uIGHV vs mutated IGHV [mIGHV]).

Results: Between November 2019 and July 2022, 114 pts were enrolled. High-risk genomic features were common, with 66 pts (57.9%) having del(17p) and/or TP53mut and 86 (75.4%) having uIGHV. Median age was 67 years (range, 26-87), 56.1% were male, and complex karyotype was present in 41.2% and 22.8% of pts using thresholds of ≥3 and ≥5 chromosomal abnormalities, respectively. As of April 15, 2026, mFU was 50.0 mo overall [57.3 mo in pts with del(17p) and/or TP53mut; 48.4 mo in those without].

Ven was discontinued or completed in all pts. At data cutoff, 66.7% of pts with del(17p) and/or TP53mut and 59.6% without remained on zanu. Fourteen pts (14.3%) met protocol-defined uMRD-guided stopping criteria and discontinued treatment; among these, three pts [all with del(17p) and/or TP53mut] subsequently developed PD, two withdrew from study while in remission, and nine remain progression free, including eight who maintained uMRD.

In the intent-to-treat population, PFS estimates were 87.2% and 84.8% at 42 and 48 mo, respectively. PFS was similar regardless of TP53 status, with 42- and 48-mo PFS estimates of 87.3% and 83.9% in pts with del(17p) and/or TP53mut and a 42-mo estimate of 86.6% in pts without. Similarly, PFS was maintained irrespective of IGHV status, with 42- and 48-mo estimates of 87.9% and 86.5% in pts with uIGHV and a 42-mo estimate of 82.9% in pts with mIGHV.

The best PB-uMRD rate was 60.5% overall and was similar in pts with and without TP53 aberrations (60.6% vs 61.7%). Median time to uMRD was longer in pts with vs without del(17p) and/or TP53mut (19.5 vs 11.3 mo). Among pts with uIGHV and mIGHV, best PB-uMRD rates were 64.0% and 45.8%, respectively.

Overall survival estimates were 93.8% at both 42 and 48 mo. Seven deaths occurred, including five attributed to adverse events (AEs; none treatment-related) and two due to PD (no Richter transformation). Safety findings were consistent with prior reports. Grade ≥3 treatment-emergent AEs of interest were neutropenia (23.7%), infections (13.2%), hypertension (9.6%), second primary malignancies (7.9%), hemorrhage (3.5%), and atrial fibrillation/flutter (1.8%).

Conclusion: With ~4 years of follow-up, zanu+ven demonstrated durable disease control and deep remission across genomic risk groups with TN CLL/SLL. PFS and best PB-uMRD rates were generally comparable between pts with and without TP53 aberrations, and durable clinical benefit was also observed in pts with uIGHV disease. Together, these findings suggest that the adverse prognostic impact historically associated with these features may be attenuated with this regimen. These data support zanu+ven as an effective potential treatment option for TN CLL/SLL irrespective of TP53 aberration or IGHV status.

Mazyar Shadman, MD, MPH: Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current equity holder in private company; Janssen - Research Funding; AstraZeneca - Research Funding; Sana Biotechnology - Research Funding; Nurix - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Morphosys/Incyte - Research Funding; AbbVie - Research Funding; Beigene - Research Funding; Genmab - Research Funding; Incyte - Research Funding; Vincerx - Research Funding; Mustang Bio - Research Funding; Merck - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Legend Bio - Research Funding; AbbVie - Research Funding; Genetech - Research Funding; Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Mustang Bio - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Legend Bio - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Kite, A Gilead company - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); Fate therapeutics - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)